All In Biotech

Drug Trial Radar · NCT05991583

A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors

A Phase I/II Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IBB0979 in Patients With Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

25

Planned (sponsor's estimate)

Start

Jul 3, 2023

Primary completion

Nov 30, 2025

Study completion Dec 30, 2025

Sponsor

Sponsor type
Industry
First posted
Aug 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, open-label, dose escalation and dose expansion study designed to characterize the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of IBB0979 in previously treated patients with locally advanced or metastatic solid tumors.

Conditions

  • Advanced Malignant Tumors

Interventions

  • IBB0979Drug

    IBB0979 should be subcutaneous injected,qw

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of adverse events (AEs) and SAEs (Phase Ⅰ)Time frame: 3 months after end event visit
  2. Dose limiting toxicities (DLTs) (Phase Ⅰ)Time frame: 21 days after first dose
  3. Objective response rate (ORR) in dose expansion (Phase Ⅱa)Time frame: Baseline through up to 1 years or until disease progression

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.